Maxim Biomedical

Executive Summary

Maxim Biomedical is a US-based contract development and manufacturing organization (CDMO) specializing in lateral flow and other immunoassay diagnostics. Founded in 1999 and headquartered in Frederick, Maryland, the company operates an FDA-registered, ISO 13485:2016 certified facility, providing end-to-end services from assay development and prototyping to commercial-scale manufacturing and fulfillment. Its diverse client base includes Fortune 100 companies, government agencies, and startups. As a privately held firm, MaximBio leverages over two decades of expertise in rapid diagnostic test production, positioning itself as a key partner in the growing point-of-care and decentralized testing markets. The company's focus on lateral flow technologies, which have seen heightened demand due to pandemic preparedness and the shift toward home-based testing, underscores its relevance in the diagnostics landscape. While financial details remain undisclosed, MaximBio's established infrastructure and regulatory compliance provide a solid foundation for capturing market share in the competitive CDMO space, particularly as global health agencies emphasize rapid and accessible diagnostic solutions.

Upcoming Catalysts (preview)

• Q3 2026New Government Contract for Pandemic Preparedness Rapid Tests65% success
• Q4 2026FDA Clearance of a Major Client's Point-of-Care Test Manufactured by MaximBio60% success
• Q2 2026Announcement of Manufacturing Capacity Expansion or New Facility70% success